PL1932522T3 - Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu - Google Patents

Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu

Info

Publication number
PL1932522T3
PL1932522T3 PL06811299T PL06811299T PL1932522T3 PL 1932522 T3 PL1932522 T3 PL 1932522T3 PL 06811299 T PL06811299 T PL 06811299T PL 06811299 T PL06811299 T PL 06811299T PL 1932522 T3 PL1932522 T3 PL 1932522T3
Authority
PL
Poland
Prior art keywords
amino
active ingredient
therapeutic agent
liver disease
disease containing
Prior art date
Application number
PL06811299T
Other languages
English (en)
Inventor
Takashi Kaneko
Eiji Kobayashi
Tokutarou Yasue
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of PL1932522T3 publication Critical patent/PL1932522T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06811299T 2005-10-07 2006-10-05 Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu PL1932522T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005295478 2005-10-07
EP06811299A EP1932522B1 (en) 2005-10-07 2006-10-05 Therapeutic agent for liver disease containing 2-amino-1,3-propanediol derivative as active ingredient
PCT/JP2006/319961 WO2007043433A1 (ja) 2005-10-07 2006-10-05 ２－アミノ－１，３－プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法

Publications (1)

Publication Number Publication Date
PL1932522T3 true PL1932522T3 (pl) 2012-09-28

Family

ID=37942676

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06811299T PL1932522T3 (pl) 2005-10-07 2006-10-05 Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu

Country Status (16)

Country Link
US (1) US8048928B2 (pl)
EP (1) EP1932522B1 (pl)
JP (1) JP5116476B2 (pl)
KR (1) KR101297302B1 (pl)
CN (1) CN101277687B (pl)
AU (1) AU2006300485B2 (pl)
BR (1) BRPI0617077A2 (pl)
CA (1) CA2624909C (pl)
CY (1) CY1112911T1 (pl)
DK (1) DK1932522T3 (pl)
ES (1) ES2385580T3 (pl)
PL (1) PL1932522T3 (pl)
PT (1) PT1932522E (pl)
RU (1) RU2421214C2 (pl)
SI (1) SI1932522T1 (pl)
WO (1) WO2007043433A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781617B2 (en) 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
EP2511262B1 (en) 2004-10-12 2017-02-01 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride
PT1932522E (pt) 2005-10-07 2012-06-26 Kyorin Seiyaku Kk Agente terapêutico para doenças do fígado contendo, como princípio activo, um derivado de 2- amino-1,3-propanodiol
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
MY146775A (en) 2006-08-08 2012-09-28 Kyorin Seiyaku Kk Amino alcohol derivative and immunosuppressive agent having same as an active ingredient
SG174028A1 (en) 2006-08-08 2011-09-29 Kyorin Seiyaku Kk Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
WO2008099781A1 (ja) * 2007-02-13 2008-08-21 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
KR101767019B1 (ko) 2008-03-24 2017-08-09 교린 세이야꾸 가부시키 가이샤 2-아미노-2-[2-[4-(3-벤질옥시페닐티오)-2-클로로페닐]에틸]-1,3-프로판디올염산염의 결정화 방법
NZ589412A (en) * 2008-05-20 2012-11-30 Kyorin Seiyaku Kk Use of a sphingosine-1-phosphate (S1P) agonist for maintance of induced remission of autoimmune or inflammatory diseases after inital treatment
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
US8526213B2 (en) 2010-11-01 2013-09-03 Micron Technology, Inc. Memory cells, methods of programming memory cells, and methods of forming memory cells
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
WO2018151873A1 (en) * 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
WO2020022507A1 (ja) 2018-07-27 2020-01-30 杏林製薬株式会社 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008943A1 (fr) * 1992-10-21 1994-04-28 Yoshitomi Pharmaceutical Industries, Ltd. Compose 2-amino-1,3-propanediol et immunosuppresseur
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
USRE39072E1 (en) * 1997-04-04 2006-04-18 Mitsubishi Pharma Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
AU4396899A (en) * 1998-07-02 2000-01-24 Kyowa Hakko Kogyo Co. Ltd. Remedies for diabetes
AU767241B2 (en) * 1998-09-14 2003-11-06 Qiang Xu Immunosuppressive agents
JP2000154151A (ja) * 1998-09-14 2000-06-06 Kyo Jo 免疫抑制剤
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
WO2001098301A1 (en) 2000-06-20 2001-12-27 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
EP1300405B1 (en) * 2000-07-13 2007-04-18 Sankyo Company, Limited Amino alcohol derivatives
JP2002053575A (ja) 2000-08-09 2002-02-19 Sankyo Co Ltd アミノアルコ−ル類
EP1315735A4 (en) * 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
US7064217B2 (en) * 2001-01-30 2006-06-20 University Of Virginia Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
DE60234318D1 (de) * 2001-02-08 2009-12-24 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
US20040087662A1 (en) * 2001-02-22 2004-05-06 Marc Bigaud Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
MXPA03008755A (es) * 2001-03-26 2004-02-18 Novartis Ag Derivados de 2-amino-propanol.
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
EP1391199B1 (en) * 2001-05-10 2008-12-10 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
JP2004534772A (ja) * 2001-05-24 2004-11-18 藤沢薬品工業株式会社 アミノアルコール誘導体
EP1424078A4 (en) * 2001-09-04 2009-03-25 Ono Pharmaceutical Co RESPIRATORY DISEASE MEDICINES COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR REGULATING AGENT
DE60235900D1 (de) * 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
JP4035759B2 (ja) 2001-11-06 2008-01-23 独立行政法人産業技術総合研究所 アミノアルコールリン酸化合物、製造方法、及びその利用方法
DE60328161D1 (de) * 2002-01-11 2009-08-13 Daiichi Sankyo Co Ltd Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung
JP2003267936A (ja) 2002-01-11 2003-09-25 Sankyo Co Ltd ベンゼン環化合物
AU2003202994B2 (en) * 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
ATE441654T1 (de) * 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
EP1482896A4 (en) * 2002-03-01 2005-11-23 Merck & Co Inc AMINO ALKYL PHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS
AU2003217764A1 (en) * 2002-03-01 2003-09-16 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
EP1549640A4 (en) * 2002-06-17 2008-08-06 Merck & Co Inc 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS
EP2508204B1 (en) * 2002-06-26 2014-09-24 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
EP1546110A4 (en) * 2002-07-30 2008-03-26 Univ Virginia COMPOUNDS WITH EFFECT ON SIGNAL TRANSMISSION BY SPHINGOSINE-1-PHOSPHATE
WO2004024673A1 (en) * 2002-09-13 2004-03-25 Novartis Ag Amino-propanol derivatives
WO2004026817A1 (ja) * 2002-09-19 2004-04-01 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
BR0314760A (pt) * 2002-09-24 2005-07-26 Novartis Ag Compostos orgânicos
TW200408393A (en) * 2002-10-03 2004-06-01 Ono Pharmaceutical Co Antagonist of lysophosphatidine acid receptor
JP4140698B2 (ja) 2002-10-18 2008-08-27 第一三共株式会社 リン酸又はホスホン酸誘導体
CA2509218C (en) * 2002-12-20 2010-09-07 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists
EP1594508B1 (en) * 2003-02-11 2012-08-08 Irm Llc Novel bicyclic compounds and compositions
EP2172472B1 (en) * 2003-02-18 2012-12-26 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor
JP2004307439A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd アミノジオール誘導体とその付加塩及び免疫抑制剤
JP2004307442A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ヘテロ環誘導体とその付加塩及び免疫抑制剤
JP2004307441A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ベンゼン誘導体とその付加塩及び免疫抑制剤
JP2004307440A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩
WO2004096757A1 (en) * 2003-04-30 2004-11-11 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
ES2383298T3 (es) * 2003-04-30 2012-06-20 Novartis Ag Derivados del amino-propanol como moduladores del receptor esfingosina-1-fosfato
JP2006528980A (ja) * 2003-05-15 2006-12-28 メルク　エンド　カムパニー　インコーポレーテッド Ｓ１ｐ受容体作働薬としての３−（２−アミノ−１−アザシクロ）−５−アリール−１，２，４−オキサジアゾール類
EP1638551B1 (en) * 2003-05-19 2011-12-21 Irm Llc Immunosuppressant compounds and compositions
GB0313612D0 (en) * 2003-06-12 2003-07-16 Novartis Ag Organic compounds
JP2005047899A (ja) 2003-07-11 2005-02-24 Sankyo Co Ltd アミノアルコール化合物
WO2005014525A2 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
WO2005014603A1 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Phosphinane compounds with immunomodulating activity
PL1660449T3 (pl) * 2003-08-28 2010-05-31 Novartis Ag Pochodne aminopropanolu
US7825109B2 (en) * 2003-08-29 2010-11-02 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
AU2004277947A1 (en) * 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
GB0324210D0 (en) * 2003-10-15 2003-11-19 Novartis Ag Organic compounds
WO2005041899A2 (en) * 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
CN1894225A (zh) * 2003-12-17 2007-01-10 默克公司 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯
TW200526548A (en) 2003-12-25 2005-08-16 Sankyo Co Ether derivatives
GB0401332D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005079788A1 (ja) * 2004-02-24 2005-09-01 Sankyo Company, Limited アミノアルコール化合物
TW200538433A (en) * 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
WO2005082841A1 (en) * 2004-02-24 2005-09-09 Irm Llc Immunosuppressant compounds and compositions
JP2005247691A (ja) 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬
GB0405289D0 (en) * 2004-03-09 2004-04-21 Novartis Ag Organic compounds
GB0411929D0 (en) * 2004-05-27 2004-06-30 Novartis Ag Organic compounds
EP1760071A4 (en) * 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
TW200611687A (en) * 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
RU2007109207A (ru) * 2004-08-13 2008-09-20 Прикис Фамэсьютикэлс, Инк. (US) Соединения-модуляторы активности рецептора сфингозин-1-фосфата (варианты), фармацевтическая композиция, содержащая указанные соединения, и способ лечения нарушения, ассоциированного со сфингозин-1-фосфатом
EP2511262B1 (en) * 2004-10-12 2017-02-01 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride
WO2006041015A1 (ja) 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
WO2006063033A2 (en) 2004-12-06 2006-06-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
TW200702326A (en) 2005-05-31 2007-01-16 Mitsubishi Pharma Corp 2-aminobutanol compound and its pharmaceutical use
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
PL1926483T3 (pl) * 2005-09-09 2011-05-31 Novartis Ag Leczenie chorób autoimmunologicznych
PT1932522E (pt) 2005-10-07 2012-06-26 Kyorin Seiyaku Kk Agente terapêutico para doenças do fígado contendo, como princípio activo, um derivado de 2- amino-1,3-propanodiol
CN101282926B (zh) 2005-10-12 2011-07-13 东亚荣养株式会社 S1p3受体拮抗剂
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
JP2009544734A (ja) * 2006-07-25 2009-12-17 アルコン リサーチ， リミテッド 目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト
US7877152B2 (en) * 2006-07-31 2011-01-25 JusJas LLC Bipolar stimulation/recording device with widely spaced electrodes

Also Published As

Publication number Publication date
PT1932522E (pt) 2012-06-26
CN101277687A (zh) 2008-10-01
EP1932522B1 (en) 2012-05-23
CN101277687B (zh) 2012-07-18
US8048928B2 (en) 2011-11-01
WO2007043433A1 (ja) 2007-04-19
KR101297302B1 (ko) 2013-08-19
RU2421214C2 (ru) 2011-06-20
ES2385580T3 (es) 2012-07-26
US20090253802A1 (en) 2009-10-08
DK1932522T3 (da) 2012-07-02
CA2624909C (en) 2013-10-01
KR20080064962A (ko) 2008-07-10
EP1932522A1 (en) 2008-06-18
CY1112911T1 (el) 2016-04-13
JPWO2007043433A1 (ja) 2009-04-16
RU2008115613A (ru) 2009-11-20
AU2006300485B2 (en) 2011-08-25
BRPI0617077A2 (pt) 2015-01-06
EP1932522A4 (en) 2010-07-07
CA2624909A1 (en) 2007-04-19
JP5116476B2 (ja) 2013-01-09
AU2006300485A1 (en) 2007-04-19
SI1932522T1 (sl) 2012-08-31

Similar Documents

Publication Publication Date Title
IL192150A0 (en) Therapeutic agent for inflammatory bowel disease containing as active ingredient 2-amino-1,3-propanediol derivative, or method for treating inflammatory bowel disease
AP2441A (en) Low-faoming aqueous formulations used for crop protection
IL191907A0 (en) Azepinoindole derivatives as pharmaceutical agents
PL1932522T3 (pl) Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
IL180916A0 (en) Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
IL179566A0 (en) Concentrated aqueous formulations for crop protection
ZA200709999B (en) Fungicidal active ingredient combination
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
ZA200805453B (en) Indanyl-and tetrahydronaphthyl-amino-azoline compounds for combating animal pests
IL201418A0 (en) Therapeutic agent for glaucoma containing adenosine derivative as active ingredient
ZA200800698B (en) Pyrazole derivatives as therapeutic agents
ZA200805452B (en) Indanyl-and Tetrahydronaphtyl-amino-thiourea compounds for combating animal pests
ZA200804757B (en) Fungicidal active ingredient combination
ZA200804952B (en) Fungicidal active substance combination
EP1776112A4 (en) HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS
HUE031355T2 (hu) Vízben nem oldódó aktív szerves vegyületek kompozíciói
PL1773307T3 (pl) Preparaty 2-amino-1,3-propanodioli i ich analogów
EP1859795A4 (en) THERAPEUTIC AGENT FOR OPHTHALMIC DISEASES
EP1884237A4 (en) NEUROCYTE PROTECTIVE AGENT COMPRISING AN AMIDINO DERIVATIVE AS AN ACTIVE SUBSTANCE
PL1876175T3 (pl) Środek terapeutyczny do leczenia chorób rogówki
ZA200700755B (en) Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
EP1958949A4 (en) THERAPEUTIC AGENT AGAINST HORNHAUT / BINDEHAUT DISEASE
KR100673974B9 (ko) 2,2-디메틸-3-알킬에테르-4-알콕시-6-알킬 아미노벤조피란 유도체를 유효성분으로 함유하는 pge2 활성에 관련된 염증질환 치료제
EP1946765A4 (en) MEANS FOR THE TREATMENT OF ANGIOGENESIS-RELATED DISEASES WITH CHROMDROMODULIN-I AS AN ACTIVE AGENT
EP1889627A4 (en) THERAPEUTIC AGENT CONTAINING EPO DERIVATIVE FOR TREATING BLOOD DISEASES